Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

(Reuters) -The lowest dose of Novo Nordisk's weight-loss drug, Wegovy, was listed as available on the U.S. health regulator's ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released headline results from part 1 of the ongoing ESSENCE Phase 3 trial, a 240-week ...

People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss ...

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...

Novo Nordisk’s drug helped reduce knee pain in osteoarthritis patients with obesity. Meanwhile, the Change Healthcare breach ...

After years in shortage, weight loss and diabetes drugs Ozempic and Wegovy are now considered to be “available” by the Food and Drug Administration. At such a critical moment in US history, we need ...

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.